Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jupiter Fund Management reports dip in 1H AuM

(Sharecast News) - Jupiter Fund Management reported a dip in assets under management for the first half of the year. Assets under management dipped from £51.4bn one year before to £51.3 at the end June.

That was partly the result of £3.4bn of net outflows.

However, the firm attributed those outflows chiefly to the anticipated changes to its Value equity team and to the management of Chrysalis Investment Trust.

Excluding those impacts, underlying net outflows were £0.2bn, Jupiter said.

Net revenues meanwhile declined by 4.0% to reach £173.7m, while the cost:income ratio worsened from 71% to 74%.

Yet underlying profit before tax was 3.2% higher at £47.9m.

That resulted in underlying earnings per share of 6.6p for the period, against 6.7p in the comparable half of 2023.

Management declared an ordinary dividend of 3.2p per share.

Share this article

Related Sharecast Articles

Morrisons to close 17 shops, 52 in-store cafes
(Sharecast News) - Morrisons announced a major restructuring plan on Monday that will see the closure of 17 convenience stores, 52 in-store cafés, and a range of other in-store services, putting 365 jobs at risk across the UK.
JPMorgan upgrades mining & metals sector to 'overweight'
(Sharecast News) - JPMorgan upgraded the global mining and metals sector to 'overweight' from 'underweight' on Monday, as it said that Rio Tinto, Antofagasta, Fresnillo & SSAB are its European key 'overweights'.
Frasers to open more than 350 Sports Direct stores in Southeast Asia, India
(Sharecast News) - Mike Ashley's Frasers Group said on Monday that it was planning to open more than 350 Sports Direct stores in Southeast Asia and India as it expends its existing partnership with MAP Active, a sports, fashion and distributor operator in south Asia.
Novo Nordisk inks deal on trial obesity drug worth up to $2bn
(Sharecast News) - Danish drugmaker Novo Nordisk has signed a deal worth up $2bn to develop, make and sell United Laboratories International's weight-loss drug candidate.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.